October 2021 Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor
October 2021 Boehringer Ingelheim and OSE Immunotherapeutics To Present Phase 1 Results with BI 765063
October 2021 OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
October 2021 OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi®
October 2021 Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial
October 2021 OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study